Vertex Pharmaceuticals Incorporated
Materials and methods for treatment of hemoglobinopathies

Last updated:

Abstract:

Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).

Status:
Grant
Type:

Utility

Filling date:

5 Feb 2019

Issue date:

8 Mar 2022